The European Partnership on One Health Antimicrobial Resistance, EUP OHAMR, launched its first international call for projects on 18 November 2025, which will explore new treatments to tackle AMR. The call “Treatments and adherence to treatment protocols”, involves 37 funding organisations from 28 different countries with an estimated total call budget of over 31 million Euro.
The call is co-funded by the European Union’s Horizon Europe funding programme. However please note that the OHAMR call does not use Horizon Europe eligibility rules or cost reimbursement rates. The OHAMR call documents outline the eligibility rules, eligible costs and reimbursement rates.
The OHAMR call will fund international consortia projects (involving at least 3 eligible countries) exploring new treatments covering patients, animals and plants affected by bacterial or fungal infections by providing new treatment options while reducing the risk of resistance.
The call has three topics:
- Topic 1 – Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
- Topic 2 – Develop tools and methods to improve adherence to treatment protocols.
- Topic 3 – Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.
Call Topics 1 & 2 – UK Information
Innovate UK is providing £1,086,000 to support UK participation.
UK-based SMEs are eligible to receive funding across all One Health settings. Other eligible UK-based organisations (academic institution, RTOs, public sector organisation, not for profit organisation) can apply for funding if they are working with a UK-based SME. Full eligibility criteria and costing rules can be found in the call documents. If you have any questions on Call Topics 1 & 2, please contact Fran Hodges (francesca.hodges@iuk.ukri.org).
Please note that the UK’s Medical Research Council is not providing funding for Call Topics 1 and 2.
Call Topic 3 – UK Information
The UK ‘s Medical Research Council (MRC) is providing £1 million to support UK participation. Details of MRC remit, as well as eligibility and costing rules can be found in the call documents.
Awards will be made through MRC on behalf of MRC and DHSC. MRC and DHSC are able to support all research areas that fall within the remit of MRC and DHSC.
If you have any questions about Call Topic 3, please contact UKRI-AMR@ukri.org.
Please note that Innovate UK is not providing funding for Call Topic 3.
-
To be eligible, the submitted pre-/full proposals must respect the following eligibility rules regarding the composition of their consortium. Consortia not respecting the following eligibility rules will be rejected without further review.
- The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).
- The consortium can include a maximum of six (6) project partners (including non-funded partners).
- The maximum number of partners can be increased to seven (7) if the consortium includes:
- at least one partner from an under-represented country or
- at least one partner where the Principal Investigator meets the definition of an Early-Career Researcher or
- a start-up, SME, or an Industry.
- For the purpose of this call, the under-represented countries are:
- Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Moldova, Poland, and Slovakia.
- A consortium cannot include more than two (2) partners requesting funding from the same funding organisation.
- A principal investigator can coordinate only one (1) submitted pre-proposal/ full proposal.
-
Drug-resistant infections are responsible for an increasing number of treatment failures, increased mortality and decreased food productivity. The inappropriate use of antibiotics, poor adherence to prescriptions, and overuse are among the main drivers of AMR, having a detrimental impact on the effectiveness of these critical medicines.
Developing novel treatment protocols or alternative strategies to treat infectious diseases and improving, preserving and reinforcing the clinical efficacy of the current antimicrobial treatments, is vital. It is also necessary to identify the barriers that prevent end users from adhering properly to the existing treatment protocols..
The aim of this first EUP OHAMR Call is to improve the treatment success rates of the patients, animals and plants affected by bacterial or fungal infections by providing new treatment options while reducing the risk of resistance in the different One Health settings.
-
Identify and develop new combination treatments using existing or innovative antimicrobials or antimicrobial with adjunctive treatments to extend drug efficacy and combat resistance.
Resistance limits the usability of many commonly-used antibiotics and antifungal agents in Human Health, Animal Health, and Plant Health.
Proposals addressing this topic should identify and develop therapies to be used in combination (combination of different antimicrobials, or combination of an antimicrobial and a non-antimicrobial that improves activity or facilitates a better targeting towards the site of infection) to reduce the development of resistance against antibacterial and antifungal treatments and extend the usability of inexpensive and readily available antimicrobials. These studies should be underpinned by scientific rationale and mechanism of action of these treatments.
In the framework of this topic, improvement of existing combination treatments is eligible (i.e. pharmacokinetics and pharmacodynamics, mode of administration). The choice of the targeted pathogens should be well justified. For the proposals having a Human Health interest, the proposed combination treatment should be directed against one of the bacterial or fungal pathogens included in the WHO priority lists.
-
Develop tools and methods to improve adherence to treatment protocols.
A low adherence to the treatment protocols by end-users (patients, farmers, citizens) leads to a decreased probability of success and to an increased risk of resistance to antibacterial and antifungal treatments.
Proposals addressing this topic should identify the reasons of poor adherence to treatment protocols (Human, Animal, Plant), and/or develop innovative tools (including digital tools) and methods (including sociological and behavioural approaches) to improve the adherence to treatment protocols and/or test and compare the efficiency of existing or innovative tools and methods on the adherence to treatment protocols.
Engagement with end-users is mandatory. The consideration of vulnerable groups, which often have reduced access to conventional health and care services, is expected.
-
Assess the impact of antimicrobials for veterinary and agricultural use on the risk of AMR transmission to humans and the environment to inform policies on the restriction of some antimicrobials for human use.
Proposals addressing this topic are expected to assess the impact of mechanisms of action, formulations, routes of administration and treatment regimens of antibacterial and antifungal drugs authorized for veterinary and agricultural use on the risk of emergence and transmission of AMR to humans and the environment.
Proposals addressing this topic should also aim to improve the formulation, dosage, delivery, routes of administration and treatment regimens (including pharmacokinetics and pharmacodynamics) currently used in the veterinary and agricultural sector, to decrease the risk of cross-resistance, or transmission to humans and the environment.
The aim is to generate evidence to support policies that restrict certain antimicrobials for exclusive human use and inform policies such as the WHO List of Medically Important Antimicrobials (pdf, who.int).
-
Wednesday 26 Nov 2025 (14.00-16.00 CET, 13.00-15.00 UK time): Webinar for applicants presenting the Call and the partner search tool. Register here.
Friday 28 Nov 2025 (11.oo-12.oo UK time): Innovate UK Webinar for UK applicants interested in participating in Call Topics 1 & 2. Click here to register for a webinar place.
Wed 3 Dec (10-11am), Tue 6 Jan (2-3pm) and Thu 22 Jan (11am-noon): Drop-in sessions for UK applicants preparing proposals under Call Topics 1 & 2. The drop-in sessions will be a chance for UK applicants to ask Innovate UK any questions they have, and will not be recorded. When you register for the 28 November Innovate UK briefing, you will also have the option to register for these drop-in sessions.
2 Feb 2026 (13:00 CET): Pre-proposal deadline
17 June 2026 (13:00 CEST): Full proposal deadline
Dec 2026-April 2027: Projects start
-
OHAMR call webpage (including call documents and how to apply)
